Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.
Co-Diagnostics, Inc is a diagnostics & research business based in the US. Co-Diagnostics shares (CODX) are listed on the NASDAQ and all prices are listed in US Dollars. Co-Diagnostics employs 39 staff and has a trailing 12-month revenue of around USD$25.7 million.
|52-week range||USD$0.8463 - USD$30.99|
|50-day moving average||USD$14.6927|
|200-day moving average||USD$15.4462|
|Wall St. target price||USD$35.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.351|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-09-17)||-100.00%|
|1 month (2020-08-27)||-100.00%|
|3 months (2020-06-26)||-100.00%|
|6 months (2020-03-26)||-100.00%|
|1 year (2019-09-26)||-100.00%|
|2 years (2018-09-26)||-100.00%|
|3 years (2017-09-26)||-100.00%|
|5 years (2015-09-23)||N/A|
Valuing Co-Diagnostics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Co-Diagnostics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Co-Diagnostics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 69x. In other words, Co-Diagnostics shares trade at around 69x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Co-Diagnostics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$8.1 million.
The EBITDA is a measure of a Co-Diagnostics's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$25.7 million|
|Operating margin TTM||31.02%|
|Gross profit TTM||USD$102,543|
|Return on assets TTM||23.91%|
|Return on equity TTM||42.38%|
|Market capitalisation||USD$407 million|
TTM: trailing 12 months
There are currently 7.8 million Co-Diagnostics shares held short by investors – that's known as Co-Diagnostics's "short interest". This figure is 18% up from 6.6 million last month.
There are a few different ways that this level of interest in shorting Co-Diagnostics shares can be evaluated.
Co-Diagnostics's "short interest ratio" (SIR) is the quantity of Co-Diagnostics shares currently shorted divided by the average quantity of Co-Diagnostics shares traded daily (recently around 4.3 million). Co-Diagnostics's SIR currently stands at 1.83. In other words for every 100,000 Co-Diagnostics shares traded daily on the market, roughly 1830 shares are currently held short.
However Co-Diagnostics's short interest can also be evaluated against the total number of Co-Diagnostics shares, or, against the total number of tradable Co-Diagnostics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Co-Diagnostics's short interest could be expressed as 0.28% of the outstanding shares (for every 100,000 Co-Diagnostics shares in existence, roughly 280 shares are currently held short) or 0.2794% of the tradable shares (for every 100,000 tradable Co-Diagnostics shares, roughly 279 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Co-Diagnostics.
Find out more about how you can short Co-Diagnostics stock.
We're not expecting Co-Diagnostics to pay a dividend over the next 12 months.
Over the last 12 months, Co-Diagnostics's shares have ranged in value from as little as $0.8463 up to $30.99. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Co-Diagnostics's is -1.6708. This would suggest that Co-Diagnostics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Co-Diagnostics has bucked the trend.
Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was founded in 2013 and is headquartered in Salt Lake City, Utah.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.